Dominant Negative α-Subunit of FTase Inhibits Effects of Insulin and IGF-I in MCF-7 Cells

We recently designed a dominant negative (DN) farnesyltransferase (FTase)/geranyl-gerahyltransferase I (GGTase I) α-subunit that when expressed in vascular smooth muscle cells decreased insulin-stimulated phosphorylation of FTase, FTase activity, amounts of farnesylated p21Ras, DNA synthesis, and ce...

Full description

Saved in:
Bibliographic Details
Published inBiochemical and biophysical research communications Vol. 291; no. 3; pp. 458 - 465
Main Authors Solomon, Curtis Scott, Goalstone, Marc Lee
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2002
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We recently designed a dominant negative (DN) farnesyltransferase (FTase)/geranyl-gerahyltransferase I (GGTase I) α-subunit that when expressed in vascular smooth muscle cells decreased insulin-stimulated phosphorylation of FTase, FTase activity, amounts of farnesylated p21Ras, DNA synthesis, and cell migration. Currently, we explored the inhibitory effects of DN FTase/GGTase I α-subunit in MCF-7 cells on IGF-1- and insulin-stimulated DNA synthesis and cell proliferation. Expression of the DN FTase/GGTase I α-subunit completely blocked IGF-1- and insulin-stimulated BrdU incorporation and cell count. DN FTase/GGTase I α-subunit inhibited insulin-stimulated phosphorylation of FTase/GGTase I α-subunit, FTase and GGTase I activity, and prenylation of p21Ras and RhoA. Expression of DN FTase/GGTase I α-subunit diminished IGF-1- and insulin-stimulated phosphorylation of ERK (extracellular signal-regulated kinase), but had no effect on IGF-1- and insulin-stimulated phosphorylation of Akt. Taken together, these data suggest that DN FTase/GGTase I α-subunit can assuage the mitogenic effects of IGF-1 and insulin on MCF-7 breast cancer cells.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0006-291X
1090-2104
DOI:10.1006/bbrc.2002.6471